Study of the Effect of Intramuscular Ephedrine on the Incidence of Nausea and Vomiting During Elective Cesarean Section
Primary Purpose
Nausea, Vomiting, Cesarean Section
Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Ephedrine [Synonyms: Ephedra, Ephedrinum]
Saline Placebo
Sponsored by
About this trial
This is an interventional prevention trial for Nausea focused on measuring Nausea, Vomiting, Cesarean Section
Eligibility Criteria
Inclusion Criteria:
- Must be pregnant with a single baby
- Must be at term in their pregnancy (estimated gestational age of at least 38 weeks)
- Must be scheduled for an elective Cesarean section
- Must be between 60-70" tall
- Must be free of severe systemic disease (ASA class I or II)
Exclusion Criteria:
- Contraindication to spinal anesthesia
- Any allergy to any of the medications included in the study
- History of pregnancy-induced hypertension or preeclampsia
- History of preexisting hypertension
- Diabetes mellitus
- Hyperemesis gravidum
- Previous perioperative nausea and vomiting
- History of motion sickness
- Women carrying a fetus with a known abnormality will also be excluded from the study
Sites / Locations
- New York-Presbyterian Hospital; Weill Medical College of Cornell
Arms of the Study
Arm 1
Arm 2
Arm Type
Placebo Comparator
Experimental
Arm Label
Saline Placebo
IM Ephedrine
Arm Description
Drug: Saline Placebo 0.5 mL, IM (in the muscle), one time
Drug: Ephedrine [Synonyms: Ephedra, Ephedrinum] 25 mg, IM (in the muscle), one time
Outcomes
Primary Outcome Measures
Pre-Induction Nausea Score
Subject's self-rated nausea level on a scale of 0-3 immediately prior to induction of spinal anesthesia, where 0=no nausea, 1=mild nausea, 2=moderate nausea, and 3=severe nausea
Subject's Self-rated Intra-operative Nausea Level on a Scale of 0-3, Where 0=no Nausea, 1=Mild Nausea, 2=Moderate Nausea, and 3=Severe Nausea.
Subjects were asked to rate their nausea level on a scale of 0-3, where 0=no nausea, 1=mild nausea, 2=moderate nausea, and 3=severe nausea, five times during their procedure: 1) Immediately prior to skin incision, 2) immediately following delivery of the baby, 3) following reinternalization of the uterus, 4) following closure of the fascia, 5) following closure of the skin.
The numbers given by the subject were then averaged to determine the average level of nausea intra-operatively for each subject.
Post-Operation Nausea Score
Subjects were asked to rate their nausea level on a scale of 0-3, where 0=no nausea, 1=mild nausea, 2=moderate nausea, and 3=severe nausea two times after the conclusion of their surgery: 1) upon arrival in the PACU, and 2) immediately prior to discharge from the PACU.
The numbers given by the subject were then averaged to determine the average level of nausea post-operative for each subject.
Secondary Outcome Measures
Full Information
NCT ID
NCT00432991
First Posted
February 7, 2007
Last Updated
April 14, 2017
Sponsor
Weill Medical College of Cornell University
Collaborators
New York Presbyterian Hospital
1. Study Identification
Unique Protocol Identification Number
NCT00432991
Brief Title
Study of the Effect of Intramuscular Ephedrine on the Incidence of Nausea and Vomiting During Elective Cesarean Section
Official Title
A Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Intramuscular Ephedrine on the Incidence of Perioperative Nausea and Vomiting During Elective Cesarean Section
Study Type
Interventional
2. Study Status
Record Verification Date
April 2017
Overall Recruitment Status
Completed
Study Start Date
February 2007 (undefined)
Primary Completion Date
September 2010 (Actual)
Study Completion Date
September 2010 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Weill Medical College of Cornell University
Collaborators
New York Presbyterian Hospital
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this research study is to investigate if the incidence of nausea and vomiting that subjects experience during and after a Cesarean section can be reduced by giving a shot of the drug ephedrine into the thigh muscle at the time of spinal anesthesia administration.
Detailed Description
This research project is designed to study the medication ephedrine, when it is given as a routine part of the anesthesia for elective Cesarean section. Ephedrine is a medication that is widely used in labor and in vaginal and operative (Cesarean section) deliveries to help maintain a woman's blood pressure within its normal range, especially after spinal and epidural anesthesia has been administered. The purpose of this study is to determine if ephedrine, when given intramuscularly (<IM> as a shot in the muscle), at the time of spinal anesthesia administration, can help to decrease the incidence of nausea and vomiting subjects experience during and after a Cesarean section. This study will compare women who receive ephedrine to a similar group of women who receive a normal saline placebo. In addition to looking at the difference in the incidence of nausea and vomiting perioperatively, this study will also evaluate if the administration of IM ephedrine helps the baby to receive more blood from the placenta after anesthesia has been administered to the mother. This will be evaluated by performing a simple blood test, drawn from the umbilical cord, after the baby is born.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Nausea, Vomiting, Cesarean Section
Keywords
Nausea, Vomiting, Cesarean Section
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
53 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Saline Placebo
Arm Type
Placebo Comparator
Arm Description
Drug: Saline Placebo 0.5 mL, IM (in the muscle), one time
Arm Title
IM Ephedrine
Arm Type
Experimental
Arm Description
Drug: Ephedrine [Synonyms: Ephedra, Ephedrinum] 25 mg, IM (in the muscle), one time
Intervention Type
Drug
Intervention Name(s)
Ephedrine [Synonyms: Ephedra, Ephedrinum]
Intervention Description
25 mg, IM (in the muscle), one time
Intervention Type
Drug
Intervention Name(s)
Saline Placebo
Intervention Description
0.5 mL, IM (in the muscle), one time
Primary Outcome Measure Information:
Title
Pre-Induction Nausea Score
Description
Subject's self-rated nausea level on a scale of 0-3 immediately prior to induction of spinal anesthesia, where 0=no nausea, 1=mild nausea, 2=moderate nausea, and 3=severe nausea
Time Frame
immediately pre-induction
Title
Subject's Self-rated Intra-operative Nausea Level on a Scale of 0-3, Where 0=no Nausea, 1=Mild Nausea, 2=Moderate Nausea, and 3=Severe Nausea.
Description
Subjects were asked to rate their nausea level on a scale of 0-3, where 0=no nausea, 1=mild nausea, 2=moderate nausea, and 3=severe nausea, five times during their procedure: 1) Immediately prior to skin incision, 2) immediately following delivery of the baby, 3) following reinternalization of the uterus, 4) following closure of the fascia, 5) following closure of the skin.
The numbers given by the subject were then averaged to determine the average level of nausea intra-operatively for each subject.
Time Frame
intra-operation
Title
Post-Operation Nausea Score
Description
Subjects were asked to rate their nausea level on a scale of 0-3, where 0=no nausea, 1=mild nausea, 2=moderate nausea, and 3=severe nausea two times after the conclusion of their surgery: 1) upon arrival in the PACU, and 2) immediately prior to discharge from the PACU.
The numbers given by the subject were then averaged to determine the average level of nausea post-operative for each subject.
Time Frame
post-operation
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Must be pregnant with a single baby
Must be at term in their pregnancy (estimated gestational age of at least 38 weeks)
Must be scheduled for an elective Cesarean section
Must be between 60-70" tall
Must be free of severe systemic disease (ASA class I or II)
Exclusion Criteria:
Contraindication to spinal anesthesia
Any allergy to any of the medications included in the study
History of pregnancy-induced hypertension or preeclampsia
History of preexisting hypertension
Diabetes mellitus
Hyperemesis gravidum
Previous perioperative nausea and vomiting
History of motion sickness
Women carrying a fetus with a known abnormality will also be excluded from the study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sharon Abramovitz, MD
Organizational Affiliation
Anesthesiology; Weill Medical College of Cornell - New York Presbyterian Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
New York-Presbyterian Hospital; Weill Medical College of Cornell
City
New York
State/Province
New York
ZIP/Postal Code
10021
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
34002866
Citation
Griffiths JD, Gyte GM, Popham PA, Williams K, Paranjothy S, Broughton HK, Brown HC, Thomas J. Interventions for preventing nausea and vomiting in women undergoing regional anaesthesia for caesarean section. Cochrane Database Syst Rev. 2021 May 18;5(5):CD007579. doi: 10.1002/14651858.CD007579.pub3.
Results Reference
derived
Learn more about this trial
Study of the Effect of Intramuscular Ephedrine on the Incidence of Nausea and Vomiting During Elective Cesarean Section
We'll reach out to this number within 24 hrs